162 related articles for article (PubMed ID: 31773211)
1. A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects.
Yurgelun-Todd DA; Renshaw PF; Goldsmith P; Uz T; Macek TA
Psychopharmacology (Berl); 2020 Feb; 237(2):317-328. PubMed ID: 31773211
[TBL] [Abstract][Full Text] [Related]
2. Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.
Macek TA; Suzuki K; Asin K; Kimura H
Int J Neuropsychopharmacol; 2020 Nov; 23(8):524-532. PubMed ID: 32598478
[TBL] [Abstract][Full Text] [Related]
3. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia.
Macek TA; McCue M; Dong X; Hanson E; Goldsmith P; Affinito J; Mahableshwarkar AR
Schizophr Res; 2019 Feb; 204():289-294. PubMed ID: 30190165
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events.
Goldsmith P; Affinito J; McCue M; Tsai M; Roepcke S; Xie J; Gertsik L; Macek TA
Drugs R D; 2017 Dec; 17(4):631-643. PubMed ID: 29103081
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.
Tsai M; Chrones L; Xie J; Gevorkyan H; Macek TA
Psychopharmacology (Berl); 2016 Oct; 233(21-22):3787-3795. PubMed ID: 27572830
[TBL] [Abstract][Full Text] [Related]
6. TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge.
Tomimatsu Y; Cash D; Suzuki M; Suzuki K; Bernanos M; Simmons C; Williams SC; Kimura H
Neuroscience; 2016 Dec; 339():180-190. PubMed ID: 27725212
[TBL] [Abstract][Full Text] [Related]
7. A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor.
Takano A; Stenkrona P; Stepanov V; Amini N; Martinsson S; Tsai M; Goldsmith P; Xie J; Wu J; Uz T; Halldin C; Macek TA
Neuroimage; 2016 Nov; 141():10-17. PubMed ID: 27423256
[TBL] [Abstract][Full Text] [Related]
8. Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an FMRI study.
Honey RA; Honey GD; O'Loughlin C; Sharar SR; Kumaran D; Bullmore ET; Menon DK; Donovan T; Lupson VC; Bisbrown-Chippendale R; Fletcher PC
Neuropsychopharmacology; 2004 Jun; 29(6):1203-14. PubMed ID: 15100698
[TBL] [Abstract][Full Text] [Related]
9. Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects.
Shcherbinin S; Doyle O; Zelaya FO; de Simoni S; Mehta MA; Schwarz AJ
Psychopharmacology (Berl); 2015 Nov; 232(21-22):4191-204. PubMed ID: 26223493
[TBL] [Abstract][Full Text] [Related]
10. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.
Suzuki K; Harada A; Suzuki H; Miyamoto M; Kimura H
Neuropsychopharmacology; 2016 Aug; 41(9):2252-62. PubMed ID: 26849714
[TBL] [Abstract][Full Text] [Related]
11. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Deakin JF; Lees J; McKie S; Hallak JE; Williams SR; Dursun SM
Arch Gen Psychiatry; 2008 Feb; 65(2):154-64. PubMed ID: 18250253
[TBL] [Abstract][Full Text] [Related]
12. Effects of ketamine on brain function during smooth pursuit eye movements.
Steffens M; Becker B; Neumann C; Kasparbauer AM; Meyhöfer I; Weber B; Mehta MA; Hurlemann R; Ettinger U
Hum Brain Mapp; 2016 Nov; 37(11):4047-4060. PubMed ID: 27342447
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous EEG/fMRI recorded during ketamine infusion in patients with major depressive disorder.
McMillan R; Sumner R; Forsyth A; Campbell D; Malpas G; Maxwell E; Deng C; Hay J; Ponton R; Sundram F; Muthukumaraswamy S
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Apr; 99():109838. PubMed ID: 31843628
[TBL] [Abstract][Full Text] [Related]
14. Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in blood flow versus change in cognitive state.
Abel KM; Allin MP; Kucharska-Pietura K; Andrew C; Williams S; David AS; Phillips ML
Hum Brain Mapp; 2003 Feb; 18(2):135-45. PubMed ID: 12518293
[TBL] [Abstract][Full Text] [Related]
15. Ketamine effects on brain function--simultaneous fMRI/EEG during a visual oddball task.
Musso F; Brinkmeyer J; Ecker D; London MK; Thieme G; Warbrick T; Wittsack HJ; Saleh A; Greb W; de Boer P; Winterer G
Neuroimage; 2011 Sep; 58(2):508-25. PubMed ID: 21723949
[TBL] [Abstract][Full Text] [Related]
16. Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects.
Mehta MA; Schmechtig A; Kotoula V; McColm J; Jackson K; Brittain C; Tauscher-Wisniewski S; Kinon BJ; Morrison PD; Pollak T; Mant T; Williams SCR; Schwarz AJ
Psychopharmacology (Berl); 2018 Jul; 235(7):1875-1886. PubMed ID: 29564482
[TBL] [Abstract][Full Text] [Related]
17. Comparison of local spectral modulation, and temporal correlation, of simultaneously recorded EEG/fMRI signals during ketamine and midazolam sedation.
Forsyth A; McMillan R; Campbell D; Malpas G; Maxwell E; Sleigh J; Dukart J; Hipp JF; Muthukumaraswamy SD
Psychopharmacology (Berl); 2018 Dec; 235(12):3479-3493. PubMed ID: 30426183
[TBL] [Abstract][Full Text] [Related]
18. Temporal dynamics of the pharmacological MRI response to subanaesthetic ketamine in healthy volunteers: A simultaneous EEG/fMRI study.
McMillan R; Forsyth A; Campbell D; Malpas G; Maxwell E; Dukart J; Hipp JF; Muthukumaraswamy S
J Psychopharmacol; 2019 Feb; 33(2):219-229. PubMed ID: 30663520
[TBL] [Abstract][Full Text] [Related]
19. Ketamine-dependent neuronal activation in healthy volunteers.
Höflich A; Hahn A; Küblböck M; Kranz GS; Vanicek T; Ganger S; Spies M; Windischberger C; Kasper S; Winkler D; Lanzenberger R
Brain Struct Funct; 2017 Apr; 222(3):1533-1542. PubMed ID: 27578365
[TBL] [Abstract][Full Text] [Related]
20. Single doses of a highly selective inhibitor of phosphodiesterase 1 (lenrispodun) in healthy volunteers: a randomized pharmaco-fMRI clinical trial.
Khalsa SS; Victor TA; Kuplicki R; Yeh HW; Vanover KE; Paulus MP; Davis RE
Neuropsychopharmacology; 2022 Sep; 47(10):1844-1853. PubMed ID: 35488084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
